Participant flow12

How many started, completed or left each group, period by period.

1 to 12 of 12

Period	Milestone	Group	Participants
Overall Study	STARTED	210 mg Brodalumab	612
Overall Study	STARTED	140 mg Brodalumab	610
Overall Study	STARTED	Ustekinumab	300
Overall Study	STARTED	Placebo	309
Overall Study	COMPLETED	210 mg Brodalumab	597
Overall Study	COMPLETED	140 mg Brodalumab	588
Overall Study	COMPLETED	Ustekinumab	291
Overall Study	COMPLETED	Placebo	300
Overall Study	NOT COMPLETED	210 mg Brodalumab	15
Overall Study	NOT COMPLETED	140 mg Brodalumab	22
Overall Study	NOT COMPLETED	Ustekinumab	9
Overall Study	NOT COMPLETED	Placebo	9

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT01708603/flow